Abstract 195P
Background
Recurrent and metastatic endometrial cancer (EC) has a poor prognosis due to limited response rates to conventional treatment. Trastuzumab duocarmazine SYD985 showed promising antitumour activity in various cancers, including endometrial cancer. In this study, we performed a mouse clinical trial to evaluate the combination of SYD985 alone and in combination with the PARP inhibitor niraparib to explore potential synergy.
Methods
A cohort of 15 HER2-expressing EC patient-derived xenograft (PDX) murine models was performed to assess the efficacy of SYD985 and Niraparib, in monotherapy or in combination. A non-binding isotype control ADC, SYD989 was also included. Treatment administration was: SYD985 and SYD989 (1 mg/kg, i.v single dose at day 1), Niraparib (40 or 50 mg/kg, oral gavage for 21 days); and Vehicle (ADC buffer plus methylcellulose [0.5%]). Plasma concentrations of total antibody, conjugated antibody and niraparib were determined at day 4. Treatment efficacy was determined by the comparing mean tumor volumes of the compound treated groups to the vehicle group throughout the duration of the study. Toxicity was evaluated by loss in body weight.
Results
Mice treated with SYD989 and niraparib as monotherapies showed the lowest response rate, with 53% (8/15) of PDX models exhibiting non-response (NR), and 40% (6/15) a partial response (PR). Importantly, PDX treated with SYD985 as monotherapy or in combination with Niraparib exhibited an enhanced response. Thirty-four (34%) of the PDX models showed a complete response to SYD985 as monotherapy, while combination with Niraparib shown an additive effect reaching up to 60% of complete response, of which 40% showed long-term CRs. Similarly, we observed an increased survival in animals treated with SYD985 alone or in combination with niraparib.
Conclusions
This study highlights a potential impact of targeted-treatment against HER2 in combination with PARP inhibitor for patients with HER2-expressing EC.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Vall d’Hebron Institute of Research.
Funding
Byondis B.V.
Disclosure
E. Colas: Financial Interests, Institutional, Research Funding: Byondis B.V.. A. Sotoca Covaleda, M. van der Vleuten, P. Groothuis: Financial Interests, Institutional, Full or part-time Employment, Employee in Byondis B.V.: Byondis B.V.. All other authors have declared no conflicts of interest.
Resources from the same session
142P - Exploring tumor mutational burden and frameshift mutations as predictors of immune checkpoint inhibitor efficacy
Presenter: Mai Hoshino
Session: Poster session 08
143P - Efficacy of immunotherapy in gastro-intestinal (GI) tumors with mismatch repair deficient (MMRd) unusual phenotype
Presenter: Emily Alouani
Session: Poster session 08
144P - Analysis of a novel predictive marker of immune checkpoint response in head and neck cancer, calculated from histopathological slides through inferred transcriptomics
Presenter: Johnathan Arnon
Session: Poster session 08
145P - Predicting the efficacy of immunotherapy in non-small cell lung cancer using machine learning based on simple clinical characteristics and biochemical indexes
Presenter: Lei Cheng
Session: Poster session 08
146P - Biomarkers and intrinsic/acquired resistance mechanisms for atezolizumab plus chemoradiotherapy in MSS locally advanced rectal cancer: An exploratory analysis of a single center, phase II study
Presenter: Wentao Tang
Session: Poster session 08
147P - Comparison of immune-checkpoint inhibitor therapy predictive marker tests microsatellite instability (MSI) and mismatch-repair deficiency (dMMR)
Presenter: Maja Nádorvári
Session: Poster session 08
148P - Clinical significance of CD4+ T cell subsets in peripheral blood for anti-PD-1/PD-L1 therapy
Presenter: Yoshimichi Haruna
Session: Poster session 08
149P - Evaluation of HLA genotype as predictive biomarker for immunological and clinical responses upon vaccination with PolyPEPI1018 cancer vaccine against colorectal cancer
Presenter: Joleen Hubbard
Session: Poster session 08
150P - Phase I/IIa trial of CD200R1 inhibitor 23ME-00610: Exploratory analyses of tissue-based and genetic biomarkers
Presenter: Albiruni Ryan Abdul Razak
Session: Poster session 08
151P - Enhanced pharmacodynamic effects upon combination of cibisatamab and FAP-4-1BBL in 3L+ mMSS CRC patients
Presenter: Ignacio Melero
Session: Poster session 08